IPALT

iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of diisopropyltryptamine and diallyltryptamine. The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT_1B, 5-HT_2A, 5-HT_2B, and 5-HT₆ receptors, but not of the serotonin 5-HT_1A receptor. It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake. The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT_2A receptor agonist than the known psychedelic drug 5-MeO-iPALT. The chemical synthesis of iPALT has been described. Derivatives of iPALT include 5-MeO-iPALT, 4-HO-iPALT, and 2-Me-iPALT. 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use. iPALT was patented by the Alexander Shulgin Research Institute in 2024.